Literature DB >> 3701419

Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas.

M J Ebersold, L M Quast, E R Laws, B Scheithauer, R V Randall.   

Abstract

Little has been written about the long-term results of transsphenoidal treatment for clinically nonfunctioning pituitary adenomas. The records of 100 patients who had undergone a transsphenoidal procedure for excision of such tumors were reviewed. Immunocytology for pituitary hormones was performed in all cases. The group consisted predominantly of null-cell adenomas, although a small number of prolactinomas and gonadotropic tumors were found. The mean diameter of the tumors at the time of detection was slightly more than 2 cm. In most cases, the presenting symptoms were due to the mass effect of the tumor (that is, visual symptoms in 72 patients, hypopituitarism in 61, headache in 36, and cranial nerve disturbance other than visual loss in 10). Radiation therapy was recommended for patients in whom subtotal removal of the adenoma was expected. Six patients developed symptomatic tumor recurrence, and 10 patients demonstrated radiographic recurrence during the 48 to 100 months (mean 73.4 months) of follow-up observation. Only three of 10 deaths during the follow-up period were due to pituitary disease or treatment.

Entities:  

Mesh:

Year:  1986        PMID: 3701419     DOI: 10.3171/jns.1986.64.5.0713

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  43 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

2.  Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas.

Authors:  J L Jameson; A Klibanski; P M Black; N T Zervas; C M Lindell; D W Hsu; E C Ridgway; J F Habener
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

3.  Experience in management of 51 non-functioning pituitary adenomas: indications for post-operative radiotherapy.

Authors:  C Alameda; T Lucas; E Pineda; M Brito; J G Uría; R Magallón; J Estrada; B Barceló
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

4.  Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions.

Authors:  P Cappabianca; A Alfieri; A Colao; D Ferone; G Lombardi; E de Divitiis
Journal:  Skull Base Surg       Date:  1999

5.  The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.

Authors:  S M Ekramullah; Y Saitoh; N Arita; T Ohnishi; T Hayakawa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 6.  Intracranial dissemination of pituitary adenoma. Case report and review of the literature.

Authors:  M T Giordana; P Cavalla; A Allegranza; B Pollo
Journal:  Ital J Neurol Sci       Date:  1994-05

7.  Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas.

Authors:  Shinji Fukui; Naoki Otani; Hiroshi Nawashiro; Akiko Yano; Takahito Miyazawa; Akira Ohnuki; Nobusuke Tsuzuki; Hiroshi Katoh; Shoichiro Ishihara; Takamoto Suzuki; Katsuji Shima
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

Review 8.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 9.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 10.  Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas.

Authors:  Annamaria Colao; Mariagiovanna Filippella; Carolina Di Somma; Simona Manzi; Francesca Rota; Rosario Pivonello; Maria Gaccione; Michele De Rosa; Gaetano Lombardi
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.